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ReassortantRotaTeq® is a pentavalent rotavirus vaccine that contains ﬁve human-bovine reassortant strains (designated G1,
G2, G3, G4, and P1) on the backbone of the naturally attenuated tissue culture-adapted parental bovine rotavirus
(BRV) strainWC3. The viral genomes of each of the reassortant strainswere completely sequenced and compared
pairwise and phylogenetically among each other and to human rotavirus (HRV) and BRV reference strains.
Reassortants G1, G2, G3, and G4 contained the VP7 gene from their corresponding HRV parent strains, while
reassortantsG1 andG2 also contained theVP3 gene (genotypeM1) fromtheHRVparent strain. TheP1 reassortant
contained theVP4 gene from theHRVparent strain and all the other gene segments from the BRVWC3 strain. The
human VP7s had a high level of overall amino acid identity (G1: 95–99%, G2: 94–99% G3: 96–100%, G4: 93–99%)
when compared to those of representative rotavirus strains of their corresponding G serotypes. The VP4 of the P1
reassortant had a high identity (92–97%)with those of serotype P1A[8] HRV reference strains, while the BRV VP7
showed identities ranging from 91% to 94% to those of serotype G6 HRV strains. Sequence analyses of the BRV or
HRV genes conﬁrmed that the fundamental structure of the proteins in the vaccinewas similar to those of theHRV
and BRV references strains. Sequences analyses showed that RotaTeq®exhibited a high degree of genetic stability
as no mutations were identiﬁed in the material of each reassortant, which undergoes two rounds of replication
cycles in cell culture during themanufacturing process,when compared to theﬁnalmaterial used toﬁll the dosing
tubes. The infectivity of eachof the reassortant strains of RotaTeq®, likeHRVstrains,didnot require thepresenceof
sialic acid residues on the cell surface. The molecular and biologic characterization of RotaTeq® adds to the
signiﬁcant body of clinical data supporting the consistent efﬁcacy, immunogenicity, and safety of RotaTeq®.Department, Merck Research
D-28, North Wales, PA 19454-
).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Rotavirus is the major etiologic agent of acute viral gastroenteritis in
children under 5 years of age worldwide (Ciarlet and Estes, 2002;
Parashar et al., 2006). Rotaviruses are triple-layered viruses that belong
to the Reoviridae family and contain a genome of 11 segments of double-
stranded (ds)RNA that encode six structural viral proteins (VP1–VP4,
VP6, and VP7) and six nonstructural proteins (NSP1–NSP6) (Ciarlet and
Estes, 2002; Estes and Kapikian, 2007). The outer protein layer is
composed of the VP4 and VP7 proteins, which independently elicit
neutralizing antibodies and induce protective immunity (Ciarlet and
Estes, 2002). Rotavirus strains are classiﬁed into protease-sensitive or P
types (VP4 is protease sensitive) and glycoprotein or G types (VP7 is a
glycoprotein) (Ciarlet and Estes, 2002). Both G and P types can bedeﬁned serologically (serotypes) or genetically based on sequence data
(genotypes). To date 15 G serotypes and 23 G genotypes have been
described in literature (Abe et al., 2009; Hoshino et al., 2002;
Matthijnssens et al., 2008a; Schumann et al., 2009; Solberg et al., 2009;
Ursu et al., 2009), and out of 31 P genotypes (designated in brackets),
only 15 P serotypes (P1A, P1B and P2 to P14) have been identiﬁed (Abe
et al., 2009; Estes and Kapikian, 2007; Matthijnssens et al., 2008a;
Schumann et al., 2009; Solberg et al., 2009). In both developed and
developing countries, N85% of rotavirus strains circulating in humans
belong to serotypes G1 to G4, or G9 in combination with serotypes P1A
[8] or P1B[4] (Santos andHoshino, 2005). Recently, a genotyping system
based on nucleotide sequences of all the 11 gene segments has been
established and a rotavirus classiﬁcation working group (RCWG) was
formed (Matthijnssens et al., 2008a,b). In this classiﬁcation system, a
nucleotide cut-off percentage was calculated to distinguish different
genotypes for each of the rotavirus gene segments. According to this
classiﬁcation system, 13 I (Intermediate capsid shell, VP6), 6 R (RNA
polymerase, VP1), 6C (Core shell, VP2), 7M(Methyltransferase, VP3), 16
A (interferon Antagonist, NSP1), 6 N (NTPase, NSP2), 8 T (Translation
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NSP5) genotypes have been established and published (Matthijnssens
et al., 2009b; Schumann et al., 2009; Solberg et al., 2009; Trojnar et al.,
2009; Ursu et al., 2009). This classiﬁcation system has been successfully
used to describe interspecies transmission and reassortments among
human rotavirus (HRV) and animal rotavirus strains (Heiman et al.,
2008;Matthijnssens et al., 2006a,b, 2008d, 2009c;McDonald et al., 2009;
Rahman et al., 2007; Small et al., 2007; Tsugawa and Hoshino, 2008).
Genome reassortment is a natural process possible among viruses
with segmented genomes when more than one virus strain infects an
individual or cell, resulting in the exchange of segments after co-
infection (Ciarlet and Estes, 2002). Due to the segmented composition
of the rotavirus genome, co-infection between two rotavirus strains
has been exploited to naturally derive reassortant vaccine strains with
desired speciﬁc combinations of genome segments derived from each
of the parental rotavirus strains (Ciarlet and Schödel, 2009). This
modiﬁed Jennerian approach has been used to develop some rotavirus
vaccines, including the pentavalent rotavirus vaccine (PRV; RotaTeq®,
rotavirus vaccine, live, oral, pentavalent; Merck Sharp & Dohme, Inc.,
Whitehouse Station, NJ, United States); designated RV5 by the
Advisory Committee on Immunization Practices [ACIP] (CDC, 2009),
which is now licensed in more than 90 countries worldwide (Ciarlet
and Schödel, 2009; Heaton and Ciarlet, 2007).
RotaTeq® contains ﬁve human-bovine reassortant strains (WI79-9,
SC2-9, WI78-8, BrB-9, and WI79-4—designated G1, G2, G3, G4, and P1,
respectively, for simplicity), each expressing a different VP7 or VP4
rotavirus surface protein, on the backbone of the naturally attenuated
tissue culture-adapted parental bovine rotavirus (BRV) strain WC3
(G6P7[5]) (Ciarlet et al., 2002a; Heaton et al., 2005). The G1–G4 strains
express one of the VP7 outer-capsid proteins (G1, G2, G3, or G4,
respectively) from the tissue culture-adaptedparentHRV strains (WI79,
SC2, WI78, or Bricout B [BrB], respectively) and the VP4 protein P7[5]
from the BRV WC3 strain, whereas the P1 strain expresses the VP4
protein P1A[8] from the parent HRV strain (WI79) and the VP7 outer
capsid protein G6 from the BRVWC3 strain (Ciarlet et al., 2002a; Ciarlet
and Schödel, 2009; Heaton and Ciarlet, 2007; Heaton et al., 2005). The
G6 serotype has been found to circulate in humans, but at amuch lower
frequency compared to serotypes, G1 to G4 and G9 (Bányai et al., 2004;
Matthijnssens et al., 2008c).
A large body of clinical data (N70,000 subjects) has shown the
vaccine to be immunogenic, efﬁcacious (98% protection against severe
and 74% protection against any rotavirus disease), and well tolerated
with respect to intussusception when compared to placebo (Vesikari
et al., 2006). The inherent properties of the vaccine, such as molecular
andbiological characteristics of the reassortant strains, and the lot-to-lot
properties, such as potency and physical/biochemical heterogeneity
introduced by the manufacturing process, are critical to maximize
vaccine performance. In this study, our aimwas to fully characterize the
molecular and biological properties of the vaccine reassortant strains,
including assigning parental origin of individual gene segments,
sequencing of the viral genomes and comparing them to human and
bovine reference rotavirus strains, evaluating requirements for initial
binding to cells, and assessing the antigenic properties of the vaccine
virus strains.Wealso evaluated the genetic stability of thevaccineduring
the manufacturing process by comparing sequence data from viral
master seed lots with those of process validation lots.
Results
Parental origin of reassortant gene segments
During derivation of the reassortant strains, electropherotyping was
performedto identify theoriginofeachgene segmentashumanorbovine.
Electropherotypingwas repeatedafter the scaleupprocess to conﬁrmthat
genetic reassortment had not occurred. As a whole, the gene segments of
each reassortant virus exhibited auniquemigrationpattern, but itwasnotpossible to unequivocally assign the parental origin of all genes (data not
shown). To deﬁnitively assign the origin of the genes in RotaTeq®, each
gene was fully sequenced and compared by alignment to a partial
sequence from each of its two parental viruses (human and bovine). In
addition, the genotype for each the 11 gene segments of the reassortant
andparental strainsweredeterminedusing theonlineRotaC classiﬁcation
tool, according to the new classiﬁcation system described by Matthijns-
sens and colleagues (Table 1) (Maes et al., 2009; Matthijnssens et al.,
2008a,b).
The VP7 gene segments of the reassortant strains G1, G2, G3, and
G4 were conﬁrmed to have the highest identity with the ones from
human parental strains WI79, SC2, WI78, and BrB respectively.
Reassortants G1 and G2 each had a human VP3 gene segment
(genotype M1) with the highest identity to human strain WI79
(Table 1). The G1 reassortant was derived ﬁrst, after 13 passages in
cell culture, and the genotype M1 VP3 gene was acquired from the
parental HRVWI79 strain. During the derivation of the G2 reassortant
(11 passages in cell culture), the G1 reassortant was used as the
parental source of the bovine genes; therefore, the G2 reassortant
retained the human VP3 gene segment from the HRV WI79 strain.
Reassortants G3, G4, and P1 were derived independently from the
BRV WC3 parent strain and the corresponding HRV parental strain
after 55, 65, and 30 passages in cell culture, respectively. The G3 and
G4 reassortant strains were shown to possess a single human gene
(VP7) while the remaining gene segments originated from the BRV
WC3 strain (Table 1). Reassortant P1 possessed one human gene, the
P1A[8] VP4 from strain WI79, while all the other gene segments were
derived from the BRVWC3 strain, including the serotype G6 VP7 gene
segment from strain WC3 (Table 1).
Molecular characterization of individual protein sequences
The sequences from each MSL reassortant rotavirus strain were
compared to common references strains to examine conservedmotifs. In
addition, phylogenetic analyseswere carried out to study the relationship
of all gene segments with cognate sequences from HRV and animal
rotavirus strains. Each gene is discussed separately below. Overall, the
bovineorhumanoriginof eachgenewas conﬁrmed, and the fundamental
structureof theproteins in thevaccinewas similar to thoseof theHRVand
BRV references strains. All common motifs were present and no
unexpected sequence changes were found. Since the reassortant strains
were derived separately from the parental strains and several passages
were necessary to derive each reassortant strain, minor sequence
differences between the reassortant strains were expected. Therefore,
the sequences of each gene and protein were also compared among the
vaccine reassortant strains. Table 2 summarizes the nucleotide and amino
acid sequence differences of each gene segment among the 5 rotavirus
reassortant vaccine strains. Unfortunately, sincenooriginalWC3calf stool
material remained, the gene sequences of the WC3 strain from calf stool
material were not determined to assess the extent of nucleotide changes
that accompanied the cell-culture adaptation of WC3.
VP1
In all of the reassortants, the VP1 was of bovine origin (Table 1) and
as expected contained an ORFwith a predicted size of 1088 amino acids
(aa). The VP1 from all ﬁve reassortant strains, as well as reference BRV
strains RF and UK, contained four conserved putative RNA-dependent
RNA polymerase motifs at residues 512–527, 582–608, 626–636, and
690–702 (data not shown) (Ito et al., 2001; Mitchell and Both, 1990).
The VP1 aa (nucleotide) identities between the vaccine reassortant
strains and the BRV reference strains RF and UK ranged from 98.3 to
99.0% (92.7–97.0%). Twonucleotide substitutionswereobservedamong
the ﬁve reassortants and both translated into changes in the protein
sequence: nucleotides 178 (G1, G2, G3=CCA→P; G4, P1=TCA→S)
and 953 (G1, G2, G3, G4=GCC→A; P1=GTC→V) (Table 2).
Table 1
Parental origin of gene segments and genomic constellations of the reassortant rotavirus strains of RotaTeq® as conﬁrmed by sequencing.
Reassortant
Rotavirus
BRV
Parent
HRV
Parent
Parental origin of genome segment (genomic constellation)a
1 2 3 4 5 6 7 8 9 10 11
(VP1) (VP2) (VP3) (VP4) (NSP1) (VP6) (NSP3) (NSP2) (VP7) (NSP4) (NSP5/6)
WI79-9 (G1) WC3 WI79 B (R2) B (C2) H (M1) B (P[5]) B (A3) B (I2) B (T6) B (N2) H (G1) B (E2) B (H3)
SC2-9 (G2) WC3 SC2 B (R2) B (C2) H (M1) B (P[5]) B (A3) B (I2) B (T6) B (N2) H (G2) B (E2) B (H3)
WI78-8 (G3) WC3 WI78 B (R2) B (C2) B (M2) B (P[5]) B (A3) B (I2) B (T6) B (N2) H (G3) B (E2) B (H3)
BrB-9 (G4) WC3 BrB B (R2) B (C2) B (M2) B (P[5]) B (A3) B (I2) B (T6) B (N2) H (G4) B (E2) B (H3)
WI79-4 (P1) WC3 WI79 B (R2) B (C2) B (M2) H (P[8]) B (A3) B (I2) B (T6) B (N2) B (G6) B (E2) B (H3)
Abbreviations: BRV, bovine rotavirus; HRV, human rotavirus; H, human; B, bovine.
a Genotypes were determined using the online RotaC classiﬁcation tool, according to the guidelines of the RCWG (Maes et al., 2009; Matthijnssens et al., 2008b). Human-derived
genome segments are in boldtype font.
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genotype (Supplementary Data 2), which is mainly composed of other
BRVs or rotaviruses believed to have originated from members of the
Bovidae family (Matthijnssens et al., 2009b).
VP2
The VP2 was of bovine origin in all of the reassortant strains
(Table 1), and contained an ORF with a predicted size of 880 aa. Two
putative leucine zipper regions at residues 526–567 (KRSIQR-Table 2
Summary of nucleotide and amino acid sequence differences of each gene segment among
the ﬁve rotavirus reassortant vaccine strains in the Master Seed Lot (MSL) material.
Genome
segment
(protein)
Nucleotide
position
Nucleotide andaminoacid changesa in indicated reassortant
strains
WI79-9
(G1)
SC2-9
(G2)
WI78-8
(G3)
BrB-9
(G4)
WI79-4
(P1)
1 (VP1) 178 CCA→P CCA→P CCA→P TCA→S TCA→ S
1 (VP1) 953 GCC→A GCC→A GCC→A GCC→A GTC→ V
2 (VP2) 671 GGC→G AGC→S GGC→G GGC→G GGC→ G
2 (VP2) 1259 CCA→P CCA→P CCA→P TCA→S CCA→ P
3 (VP3) 1459 N/Ab N/Ab AAT→N GAT→D AAT→ N
3 (VP3) 2217c N/Ab N/Ab GGT→G GGT→G GGC→ G
4 (VP4) 520 AGA→R GGA→G GGA→G GGA→G N/Af
4 (VP4) 588d AAT→N AAN→X AAG→K AAG→K N/Af
4 (VP4) 1102 GTG→V GTG→V GTG→V ATG→M N/Af
4 (VP4) 1181e GTC→V GTC→V GTC→V GNC→X N/Af
4 (VP4) 1915 ATA→ I ATA→ I ATA→ I GTA→V N/Af
5 (NSP1) 122 TGG→W TGG→W TGG→W TGG→W TGC→C
5 (NSP1) 979 TCA→S TCA→S TTA→L TCA→S TCA→S
5 (NSP1) 1261 TTA→L TTA→L TTA→L TTA→L TCA→S
6 (VP6) 485c AAA→K AAA→K AAG→K AAA→K AAA→K
6 (VP6) 974c CAC→H CAC→H CAC→H CAC→H CAT→H
7 (NSP3) 178 GAT→D GAT→D GAT→D GAT→D GAG→E
7 (NSP3) 309 GAT→D GAT→D GAT→D GAT→D GCT→A
11 (NSP5/6) 257 ATG→M ATG→M ATG→M ATG→M ACG→T
Note: No nucleotide substitutions were observed among the ﬁve reassortant strains
in genome segment 8 (NSP2) or 10 (NSP4). The VP7 genes (segment 9) and their
corresponding VP7 proteins of the G1, G2, G3, G4 and P1 reassortant strains exhibited 72.7–
83.1% and 72.6–76.7% nucleotide and amino acid identity among each other, respectively,
clearly establishing that each reassortant strain belongs to a different VP7 G genotype.
a The nucleotide in boldtype corresponds to the base position in the codon where a
differencewasobserved. The letter after thearrowcorresponds to theabbreviatedaminoacid.
b N/A, or not applicable. The origin of genome segment 3 of the G1 and G2 reassortant
strains is human, while that of the G3, G4, and P1 reassortant strains is bovine.
c The nucleotide change at this position does not result in an amino acid change.
d The nucleotide at this position is labeled an “N” in the G2 reassortant strain due to a
dimorphic base of both “T” and “G” in the sequence data. Therefore, the amino acid
corresponding to this codon is labeled as X in the protein sequence data because it could
translate into a K or N in the protein.
e The nucleotide at this position is labeled an “N” in the G4 reassortant strain due to a
dimorphic base of both “T” and “C” in the sequence data. Therefore, the amino acid
corresponding to this codon is labeled as X in the protein sequence data because it could
translate into a V or A in the protein.
f N/A, or not applicable. The origin of genome segment 4 of the P1 reassortant strain
is human, while that of the G1, G2, G3, and G4 reassortant strains in bovine.GILLLSNRLGQLVDLTRLLAYNYETLMACVTMNMQH) and 655–696
(ARVPDD QMYRLRDRLRLLPVEVRRLDIFNLILMNMDQIERAS) that are
conserved in some human, bovine, and simian strains (Kumar et al.,
1989; Mitchell and Both, 1990) were found in all ﬁve reassortant
viruses, as well as in the BRV RF and UK strains (data not shown).
These regions were not conserved in an avian rotavirus strain (Ito
et al., 2001), hence the function and importance of these motifs are
unclear. The recent x-ray crystal structure of VP2 indicates that this
protein lacks a leucine zipper (McClain et al., 2010).
The VP2 amino acid (nucleotide) identities between the reassor-
tant vaccine strains and the BRV reference strains RF and UK ranged
from 98.6% to 99.4% (96.7–97.0%). Nucleotide substitutions occurred
among the ﬁve reassortant viruses at two sites and both translated
into changes in the protein sequence: nucleotides 671 (G1, G3, G4,
P1=GGC→G; G2=AGC→A) and 1259 (G1, G2, G3, P1=CCA→P;
G4=TCA→S) (Table 2). Phylogenetically, all 5 reassortants clustered
within the C2 genotype and were closely related to other BRVs
(Supplementary Data 3).
VP3
The VP3 was of human origin in reassortants G1 and G2, and of
bovine origin in reassortants G3, G4 and P1 (Table 1). As expected,
each of the genes contained an ORF with a predicted size of 835 aa.
Each of the ﬁve reassortant virus VP3 proteins, as well as those from
BRV (RF, UK) and HRV (KU) reference strains contained the main
structure of conserved aa stretches (residues 159–166, 245–261, 383–
392, and 541–547) that have been found in rotaviruses from many
different species (data not shown) (Cook and McCrae, 2004; Ito et al.,
2001). The human VP3 proteins were not identical to the bovine
sequences in these conserved regions. Residues 245, 251, and 384
were conserved within each species, but differed between them. No
nucleotide substitutions were detected between the VP3 of reassor-
tants G1 and G2, but two differenceswere observed among the G3, G4,
and P1 reassortants, only one of which resulted in an aa change:
nucleotides 1459 (G3, P1=AAT→N; G4=GAT→D) and 2217 (G3,
G4=GGT→G; P1=GGC→G) (Table 2).
The human VP3 proteins (genotype M1) in the G1 and G2
reassortants were compared to a number of human strains belonging
to twogenetically distinct groups:Wa, ST3, KU, andWI-61 (belonging to
the Wa-like genogroup, comprising the typical human G1P[8], G3P[8],
G4P[8] and G9P[8] strains), and DS-1, 69 M and TB-Chen (belonging to
the DS-1 like genogroup, comprising the typical human G2P[4] strains).
The VP3 proteins of the G1 and G2 reassortant strains showed an aa
(nucleotide) sequence identity of 94.8–99.0% (92.4–99.0%) to those of
theWa-like strains and 81.3–81.4% (76.4–77.6%) identity to those of the
DS-1-like strains. The bovine VP3 proteins (genotype M2) of the
reassortants G3, G4, and P1 were compared to those of BRV references
strain RF and UK and were found to be 96.9–97.5% (93.2–93.9%)
identical. The aa (nucleotide) identity between the human and bovine
VP3 proteins of the reassortants of RotaTeq® was 81.9% (76.2%) which
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nucleotide sequence identities between BRV andHRV strains (Cook and
McCrae, 2004). The bovine VP3 proteins (genotype M2) possessed a
80.7–82.0% (76.2–77.6%) identity with the Wa-like (genotype M1)
group of HRV reference strains and an 89.8–97.6% (82.8–93.7%) identity
with theDS-1-like groupofHRV reference strains (genotypeM2),which
is not surprising since human DS-1-like and BRV are believed to have a
common origin (Matthijnssens et al., 2008a). Phylogenetically, the VP3
of the G1 and G2 reassortants clustered closely with human Wa-like
reference strains in theM1genotype, as expected (Fig. 1). TheVP3 of the
G3, G4 and P1 reassortants clustered together within the M2 genotype
(Fig. 1) and were closely related to other BRVs or rotaviruses which are
believed to have originated from members of the Bovidae family
(Matthijnssens et al., 2009b).Fig. 1. Phylogenetic tree based on the full length nucleotide sequences of the rotavirus VP3
genotypes included in the vaccine are shown for simplicity. The other VP3M genotypes are re
as the parental BRV WC3 strain, whose VP3 sequence was determined previously (Matthijn
origin/strain name. Abbreviations: Hu, human; Bo, bovine, Gu, guanaco; Ov, ovine; An, antVP4
Reassortant strains G1, G2, G3, and G4 shared the sameVP4 fromBRV
strain WC3 (P7[5]), while the P1 reassortant strain possessed the VP4
from the HRV strain WI79 (P1A[8]) (Table 1). The ORFs of the BRV and
HRV VP4 genes had a predicted size of 776 and 775 aa, respectively. Like
most rotavirus strains, the VP4 of the ﬁve reassortant viruses contained
conserved arginines (trypsin cleavage sites) at residues 231, 241, and582
(Arias et al., 1996; Estes and Kapikian, 2007); furthermore, they also
contained a trypsin cleavage site at aa 258 (lysine) and a putative site at
aa467 (Crawford et al., 2001) (Fig. 2). TheVP4of theP1 reassortant strain
contained a trypsin cleavage site at arginine 247, which is not conserved
in P7[5] strains, and therefore, was not present in the reassortants with
the BRV P7[5] VP4 gene. Rotaviruses of serotypes P7[5] and P1A[8]genes. Bootstrap values (500 replicates) above 70 are shown. Only the M1 and M2 VP3
presented by their genotype number. The reassortant vaccine strains are shaded, as well
ssens et al., 2008a), are shaded. For each strain the following data are given: species of
elope.
Fig. 2. Comparison of the VP4 sequences of the reassortant strains of RotaTeq®. The highly conserved cysteines (●), prolines (▼) and arginines (■) are indicated. The conserved
putative trypsin-cleavage sites are indicated by an arrow (↓). A period (.) represents a conserved position. A dash (-) represents a sequence gap. Nucleotides at positions 588 (G2)
and 1181 (G4) were not resolved; therefore, the aa was labeled “X.” The variable regions of VP4 (aa 71–204 and 578–608) (Estes and Kapikian, 2007) are shaded.
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117J. Matthijnssens et al. / Virology 403 (2010) 111–127contain four conserved cysteines at positions 216, 318, 380, and 774
(Ciarlet et al., 2002a), which were also conserved in the reassortant
strains (Fig. 2). Among the reassortants with a BRV VP4, ﬁve nucleotides
differences were found and all resulted in aa changes: nucleotides 520
(G1=AGA→R; G2, G3, G4=GGA→G), 588 (G1=AAT→N;
G2=AAN→X; G3, G4=AAG→K), 1102 (G1, G2, G3,=GTG→V;
G4=ATG→M), 1181 (G1, G2, G3=GTC→V; G4=GNC→X), and
1915 (G1, G2 , G3=ATA→ I; G4=GTA→V) (Table 2). The nucleotides
labeled ‘N’ at positions 588 (G2) and 1181 (G4) are due to unresolved
bases. The unresolved bases do not indicate the presence of mutations or
a sequencing anomaly, but were identiﬁed as polymorphisms in the
sequences at these locations.
The HRV and BRV VP4s from the reassortant strains were compared
in a phylogenetic analysis to a wide range of strains representing all
currently described P genotypes, including P1A[8] and P7[5] (Fig. 3,
Supplementary Data 4). In Fig. 3, the P1A[8] genotype has been
subdivided into several lineages, adapted from Espinola et al. (2008),
showing that the P1A[8] VP4 of the P1 reassortant clustered within
lineage 2 andwas closely related to P1A[8] HRV strains isolated in Japan,
Brazil, United States in the 1970s, 1980s and early 1990s. As expected,
the BRV WC3 P7[5] VP4 genes of the G1, G2, G3, and G4 reassortants
clusteredwith BRVs and a fewporcine rotavirus strains belonging to the
P7[5] genotype (Fig. 3, Supplementary Data 4). The previously
sequenced (Ciarlet et al., 2002a) VP4 gene of the BRV WC3 strain did
not cluster very closelywith those of theG1, G2, G3, andG4 reassortants
despite being from the same BRV strain. However, the BRV WC3 strain
used to sequence the VP4 gene ofWC3was passaged extensively in cell
culture in another laboratory before undergoing several additional
plaque puriﬁcation steps, which could have selected another WC3
variant present in the original population.
NSP1
NSP1 was of bovine origin in all of the reassortant strains (Table 1)
and possessed anORFwith a predicted size of 492 aa. Even thoughNSP1
is the most variable of all the rotavirus proteins, a highly conserved
cysteine rich motif that spans aa 42–72 (C-X2-C2-X7-C-X2-C-X3-H-X-C-
X2-C-X5-C) (Hua et al., 1993; Taniguchi et al., 1996) was found in all the
reassortant viruses, as well as in BRV reference strains RF and UK (data
not shown). Eleven highly conserved proline residues, conserved
among most group A rotaviruses (Hua et al., 1993), were also present
in all ﬁve reassortant strains (data not shown). The NSP1 amino acid
(nucleotide) identities between the reassortant vaccine strains and the
BRV reference strains RF and UK ranged from 92.6 to 99.2% (88.2–
98.4%). Nucleotide substitutions were identiﬁed among the ﬁve
reassortant viruses at three sites and all three resulted in aa changes:
nucleotide positions 122 (G1, G3, G2, G4,=TGG→W; P1=TGC→C),
979 (G1, G2, G4, P1=TCA→S; G3=TTA→L), and 1261 (G1, G2, G3,
G4=TTA→L; P1=TCA→S) (Table 2). In the 5' non-coding region of
the NSP1 gene of the G4 reassortant, a single insertion of a T was noted
compared to the other reassortants in a stretch of several consecutive T
residues (data not shown). Similar variations (single nucleotide
insertions en deletions) are present in many known 5'-end regions of
NSP1 sequences of numerous RV species (Hua et al., 1993). Phyloge-
netically, all 5 reassortants clustered together within the A3 genotype
and were closely related to other BRVs (Supplementary Data 5).
VP6
The VP6 gene segment in all ﬁve reassortant viruses was of bovine
origin and contained an ORFwith a predicted size of 397 aa. VP6 of theFig. 3. Phylogenetic tree based on the full length nucleotide sequences of the rotavirus VP4 g
genotypes included in the vaccine are shown for simplicity. The other VP4 P genotypes are
several lineages adapted from Espinola and colleagues (Espinola et al., 2008). The reassortant
was determined previously (Ciarlet et al., 2002a). For each strain the following data are givbovine parental strain WC3 was thoroughly characterized in a
previous study (Ciarlet et al., 2002a). As was found for WC3, the
VP6 of the reassortant viruses and also of the BRV reference strains RF
and UK contained 17 conserved proline residues and three conserved
cysteine residues (data not shown). The VP6 aa (nucleotide) identities
between the reassortant vaccine strains and the BRV reference strains
RF and UK ranged from 99.0 to 100% (97.4–98.2%). Two nucleotide
differences were found among the ﬁve reassortants, neither of which
translated to the protein: nucleotides 485 (G1, G2, G4, P1=AAA→K;
G3=AAG→K) and 974 (G1, G2, G3, G4=CAC→H; P1=CAT→H)
(Table 2). Phylogenetically, all 5 reassortants clustered together
within the I2 genotype closely related to other BRVs, rotaviruses
which are believed to have originated from members of the Bovidae
family (Matthijnssens et al., 2009b), or a few unusual equine and
simian rotaviruses (Supplementary Data 6).
NSP3
The gene for NSP3 (segment 7) was of bovine origin in all ﬁve
reassortant viruses and contained anORFwith a predicted size of 310 aa.
Three cysteines at positions 123, 139, and 306 that are conserved in BRV
strains (Mattion et al., 1992) were present in all the reassortant viruses
(data not shown). The NSP3 T6 genotype sequences of the reassortant
strains possessed an aa (nucleotide) identity of 99.0% (98.5%) when
compared to the BRV reference strain RF (genotype T6), and a lower
identity of 89.6% (82.8%) to reference strain UK, which is not surprising
as the NSP3 of BRV UK belongs to a different genotype, T7
(Matthijnssens et al., 2008a). There were two nucleotide substitutions
among the reassortant genes, both translated into differences in the
protein: nucleotides 178 (G1, G2, G3, G4=GAT→ D; P1=GAG→ E)
and 309 (G1, G2, G3, G4=GAT→D; P1=GCT→A) (Table 2). Phylo-
genetically, all 5 reassortants clustered together within the T6 genotype
and were closely related to other BRVs (Supplementary Data 7).
NSP2
The NSP2 genes (segment 8) of all the reassortant viruses were of
bovine origin with a predicted ORF of 317 aa. The highly conserved
basic region domain, identiﬁed in mammalian rotaviruses (12, 26),
which stretches from positions 205 to 241 and may be a putative RNA
binding domain (Patton et al., 1993), was identical in the ﬁve
reassortant viruses and in the BRV reference strains RF and UK (data
not shown). The NSP2 aa (nucleotide) identities between the vaccine
strains and the bovine reference strains RF and UK ranged from 95.6 to
96.8% (89.0–96.2%). No nucleotide substitutions were observed
among the ﬁve reassortants genes. Phylogenetically, all 5 reassortants
clustered together within the N2 genotype andwere closely related to
other BRVs (Supplementary Data 8).
VP7
The VP7 glycoprotein was of human origin in the G1, G2, G3, and G4
reassortants, while it was of bovine (WC3) origin in the P1 reassortant
strain (serotype G6). The major ORF of the VP7 genes of all the
reassortant strains contained a protein with a predicted size of 326 aa.
The VP7 proteins of all ﬁve reassortant strains contained the conserved
cleavage site at the glutamine at position 51 (Stirzaker et al., 1987) and
contained all previously identiﬁed conserved prolines and cysteines
(Ciarlet and Estes, 2002) (Fig. 4). The G1 and P1 reassortant strains each
possessed two potential N-linked glycosylation sites at positions 69 and
238, the G2 reassortant possessed three potential glycosylation sites atenes. Bootstrap values (500 replicates) above 70 are shown. Only the P1A[8] and P7[5]
represented by their genotype number. The P1A[8] genotype is further subdivided into
vaccine strains are shaded, as well as the parental BRVWC3 strain, whose VP4 sequence
en: species of origin/strain name. Abbreviations: Hu, human; Bo, bovine, Po, porcine.
Fig. 4. Comparison of the VP7 sequences of the reassortant strains of RotaTeq®. The conserved glutamine cleavage site is indicated (■). Potential N-linked glycosylation sites are
shown in boxes. Cysteine (●) and proline (▼) residues conserved in all strains are indicated. The VP7 antigenic regions are shadowed. A period (.) represents a conserved position.
The nine variable regions (VR1-VR9), identiﬁed in VP7 (aa positions 91–25, 25–29, 37–54, 65–76, 89–101, 119–132, 141–150, 208–224, and 235–242, respectively) (Ciarlet et al.,
1997; Dyall-Smith et al., 1986) are shaded. Variable regions 5, 7, 8, and 9, corresponding to antigenic regions A, B, C, and F, respectively (Ciarlet et al., 1994, 1997; Dyall-Smith et al.,
1986), include the antigenic epitopes that deﬁne serotypes.
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possessed only one site at position 69 (Fig. 4). The number of potential
N-linked glycosylation sites of each reassortant strainwas in accordance
with those expected for G1, G2, G3, G4, and G6 rotavirus strains (Ciarlet
and Estes, 2002; Ciarlet et al., 1997, 2002a; Dyall-Smith et al., 1986). The
VP7 antigenic regions, A (aa 87–101), B (aa 143–152), C (aa 208–224),
and F (aa 235–242) that deﬁne the VP7 serotypes (Ciarlet et al., 1994,
1997; Dyall-Smith et al., 1986), of the ﬁve reassortant strains clearly
supported their respective serotype classiﬁcation, with minimal aa
substitutions within each serotype (Fig. 4 and data not shown).
The VP7 sequences of the 5 reassortant viruses were compared in a
phylogenetic analysis to a wide range of HRV and animal rotavirus
strains representing all currently described genotypes (Supplemental
Data 9). The G1 genotype has been subdivided into lineages according to
Arista et al. (2006) and the G1 reassortant clustered within the G1
lineage 3, together with HRV reference strainsWa, D, and KU, and other
HRV strains isolated in Israel, Brazil Egypt, and Japan (Fig. 5A and
Supplemental Data 10). The G2 genotype has also been subdivided into
lineages (Paul et al., 2008), and the G2 reassortant clustered within the
G2 lineage 2, closely related toHRV strains isolated in SouthAfrica, China
and Australia (Fig. 5B and Supplemental Data 11). The G3 genotype
contains a very diverse group of rotaviruses isolated from many host
species (Ciarlet et al., 1997; Lazdins et al., 1995; Matthijnssens et al.,Fig. 5. Phylogenetic trees based on the full length nucleotide sequences of rotavirus VP7 gene
3, comprising reassortant G1 (see also Supplemental Data 9 and 10). (B) Detail of the G2 subl
the major HRV subcluster inside the G3b phylogenetic dendrogram, comprising the reasso
reassortant G4 (see also Supplemental Data 9). (E) Detail of the G6 genotype comprising r
bovine WC3-strain are shaded. For each strain the following data are given: species of orig
antelope.2008a). In addition to a few small groups, two large subgroups (G3a and
G3b) have been established (Matthijnssens et al., 2008a). The G3a
subgroup contains mainly animal rotaviruses isolated from horses,
rabbits, dogs, and a few strains from humans, macaques and goats,
whereas the G3b subgroup contains HRV and porcine G3 strains, with
the human rotavirus strains forming amonophyletic cluster (Matthijns-
sens et al., 2008a). The G3 reassortant of RotaTeq® clustered within the
humanmonophyletic cluster (Fig. 5C andSupplementalData 12), closely
related to HRV G3P1A[8] strains isolated in the US in the 1970s, 1980s
and 1990s (McDonald et al., 2009). The G4 genotype contains mainly
HRV rotavirus strains, with a few scattered porcine strains, and the G4
reassortant strain clustered within the largest HRV G4 subcluster, not
very closely related to any other HRV G4 strain (Fig. 5D). The P1
reassortant strain, which belongs to serotype G6, a serotype mainly
composed of BRV and HRV strains and a few rotavirus strains isolated
from pigs, antelopes and goats (Bányai et al., 2009b; Ciarlet and Estes,
2002; Matthijnssens et al., 2009b, 2008c), clustered within a large
genotype G6 subcluster that only contains BRVs (Fig. 5E).
In pairwise comparisons among the aa (nucleotide) VP7 sequences
of the 5 reassortants (across serotypes), the identity ranged from
72.7% to 83.1% (72.6–76.7%). When comparing the VP7 of each
individual reassortant to other available sequences of strains with the
same serotypes (within serotype), identities for G1, G2, G3, G4 and G6s. Bootstrap values (500 replicates) above 70 are shown. (A) Detail of the G1 sublineage
ineage 2, comprising reassortant G2 (see also Supplemental Data 9 and 11). (C) Detail of
rtant G3 (see also Supplemental Data 12). (D) Detail of the G4 genotype comprising
eassortant P1 (see also Supplemental Data 9). The reassortant strains and the parental
in/strain name. Abbreviations: Hu, human; Bo, bovine, Po, porcine; Capr, caprine; An,
119J. Matthijnssens et al. / Virology 403 (2010) 111–127
120 J. Matthijnssens et al. / Virology 403 (2010) 111–127(P1 reassortant strain) ranged from 91.0 to 99.0% (84.1–99.2%), 87.8–
100% (82.9–98.7%), 86.2–99.4% (78.0–99.1%), 89.4–97.4% (82.7–
97.3%), and 87.2–97.2% (80.7–98.3%), respectively.
NSP4
The NSP4 gene was of bovine origin in all ﬁve reassortant strains
(Table 1). TheNSP4 gene contained amajor ORFwith a predicted size of
175 aa. The ﬁve reassortants, aswell as the BRV reference strains RF and
UK contained two putative N-linked glycosylation sites at aa 8 and 18
(data not shown), which are conserved in all mammalian group A
rotaviruses sequenced todate (Chanet al., 1988; Ciarlet et al., 2000). The
NSP4 aa (nucleotide) identities between the reassortant vaccine strains
and the BRV reference strains RF and UK ranged from 97.1% to 98.3%
(97.3–97.5%). No nucleotide sequence differences in the viral entero-
toxin NSP4 gene segment were found among the ﬁve reassortant
viruses. Phylogenetically, all 5 reassortants clustered together within
the E2 genotype closely related to other BRVs (Supplementary Data 13).
NSP5 and NSP6
NSP5 and NSP6 are encoded by a single gene, which was of bovine
origin in all of the reassortants viruses (Table 1). As expected (Ciarlet
and Estes, 2002), the gene contained two major ORFs: NSP5 was the
larger of the two, and NSP6 was shorter and out of phase. The
predicted sizes of NSP5 and NSP6 were 198 and 98 aa, respectively.
The NSP5 of the ﬁve reassortants, like in all mammalian rotaviruses,
was rich in serine and threonine residues, which serve as phosphor-
ylation sites (data not shown) (Ciarlet and Estes, 2002). The NSP5 aa
(nucleotide) identities between the reassortant vaccine strains and
the BRV references strain RF and UK ranged from 94.4% to 98.5%
(97.3–97.5%) for NSP5, and 89.8% to 97.0% to (95.3%–99.0%) for NSP6.
One nucleotide difference was found among the ﬁve reassortant
genes, at position 257 (G1, G2, G3, G4=ATG→M; P1=ACG→T)
(Table 2). This substitution resulted in an aa change in the NSP6
protein only. Phylogenetically, the NSP5 sequences of all 5 reassor-
tants clustered together within the H3 genotype closely related to
other BRV rotaviruses (Supplementary Data 14).
Sequence comparison of master seed lot (MSL) and process validation lot
(PVL)
MSL sequences of all eleven genes and twelve proteins from all ﬁve
reassortant viruses of the MSL material were compared to those of PVL
material, which are generated following two additional cell passages. No
nucleotide changes were found between the MSL and PVL of any of the
reassortant strains. However, polymorphisms were detected at four
different nucleotide positions (G2 MSL VP4 position 588, G4 MSL VP4
position1181, P1 PVLVP4position 1177, andP1PVLVP7position302). In
order to eliminate the possibility of a sequencing anomaly as the cause of
these polymorphisms, short sequences ﬂanking the affected bases were
cloned into a plasmid vector froma pool of puriﬁed geneticmaterial from
each reassortant; the clones were ampliﬁed and sequenced. In each case,
the nucleotide present in the PVL was also present in the MSL (Table 3).Table 3
Ratios of nucleotides detected in master seed lot (MSL) and process validation lot (PVL) sa
Reassortant rotavirus
strain
Gene segment
(position)
MSL
No. of clones
SC2-9 (G2) VP4 (588) 14
BrB-9 (G4) VP4 (1181) 16
WI79-4 (P1) VP4 (1177) 16a
WI79-4 (P1) VP7 (302) 14
a At position 1177, in the VP4 of the P1 reassortant strain, in the MSL, one clone containThe relative frequency of dimorphic nucleotides between MSL and PVL
were not identical, but it is clear that the differences were not introduced
as a result of the manufacturing process. In other words, no mutations
were introduced in the PVL material, which is the one used to formulate
the ﬁnal vaccine dosing tube that will be administered to infants.
Antigenic characterization
Traditionally, a distinct G (VP7) serotype is deﬁned as a reciprocal
20-fold or greater difference between thehomologous andheterologous
neutralization titerwhen a new strain is tested against antisera raised to
prototype rotavirus strains of known G serotypes (Ciarlet and Estes,
2002). However, cross-reactivity can be observed if the rotavirus strains
share the same VP4 serotype-speciﬁcity because two-way cross
neutralization can be mediated by a shared P (VP4) serotype between
rotavirus strains with distinct G (VP7) serotypes (Ciarlet and Estes,
2002; Ciarlet et al., 1997; Matsuda et al., 1993; Snodgrass et al., 1992).
For this reason, a systematicmethod to typeVP7andVP4 serotypes now
involves the preparation of reassortants containing knownVP4 andVP7
genes tounequivocally interpret the cross-neutralization results (Ciarlet
and Estes, 2002; Hoshino et al., 2002).
The level of antigenicity of each VP4 or VP7 protein can vary due its
sequence, but also due to the speciﬁc VP4/VP7 combination of a
particular virion (Chen et al., 1992; Ciarlet et al., 1997; Lazdins et al.,
1995). Each of the ﬁve reassortant strains of RotaTeq® belongs to a
distinct VP7 G serotype and the G1, G2, G3, and G4 reassortant strains
share the same VP4 P serotype (P7[5]). In short, each reassortants strain
contains a different VP4/VP7 combination and theP1 reassortant strain is
the only vaccine component that does not share VP4 or VP7 serotype
speciﬁcities with any of the other reassortant vaccine strains.
Table 4 shows the antigenic characterization of the ﬁve reassortant
strains by cross-neutralization studies using hyperimmune sera raised to
each of the reassortant strains. The cross-neutralization assays using
hyperimmune serum raised to these reassortants showed that the
homotypic neutralization titer was generally higher than that of the
heterotypic responses. However, the data indicated some level of cross-
reactivity against thedifferent reassortant strains, especially those sharing
the same VP4 serotype (P7[5]). Of note, the antiserum raised to the G2
reassortant strain (G2P7[5])neutralized theG2andG3 reassortant strains
to equal titers (819,000) and theG1andG4 reassortant strainswithonly a
2-fold difference (409,600). Antisera raised to the G1, G3 and G4
reassortant strains also exhibited some level of cross-reactivitywith some
of the P7[5]-containing reassortant strains, varying from an 8- to 16-fold
difference between the neutralization titers, again possibly because the
reassortant strains share the same VP4 serotype.
Although the G1, G2, and G4 reassortant strains share the same VP4
type (P1A[8]) as the G3 reassortant strain, there was no heterotypic
response when the G1 or G2 reassortants were tested with hyperim-
mune serum raised to the G3 reassortant, but there was some low level
(16-fold) of cross-neutralization with the G4 reassortant. However,
hyperimmune sera raised to the G1 and G2 reassortants effectively
neutralized the G3 reassortant. None of the sera raised to each of the G1,
G2, G3, or G4 reassortant strains generated a neutralizing response to
the P1 reassortant, which was not unexpected since they share neithermples at identiﬁed nucleotide polymorphism sites.
PVL
Ratio No. of clones Ratio
T=9/G=5 14 G=10/T=5
T=10/C=6 16 T=12/C=0
G=5/C=10 16 G=5/C=11
C=13/A=1 14 C=3/A=7
ed a “T.” This base was not found in the PVL.
Table 4
Antigenic characterization of reassortant rotavirus vaccine strains of RotaTeq® by cross-neutralization.
Rotavirus strains VP4 (P) serotype
[genotype]
VP7 (G)
serotype
Reciprocal of neutralization antibody titera with antiserum to reassortant rotavirus vaccine
strains:
WI79-9 (G1) SC2-9 (G2) WI78-8 (G3) BrB-9 (G4) WI79-4 (P1)
Reassortant strains
G1 (WC3 x WI79 [WI79-9]) P7[5] G1 819,200 409,600 (2) 51,200 (32) 102,400 (16) 12,800 (64)
G2 (WC3 x SC2 [SC2-9]) P7[5] G2 51,200 (16) 819,200 51,200 (32) 102,400 (16) 12,800 (64)
G3 (WC3 x WI78 [WI78-8]) P7[5] G3 102,400 (8) 819,200 (1) 1,638,400 102,400 (16) 102,400 (8)
G4 (WC3 x BrB [BrB-9]) P7[5] G4 102,400 (8) 409,600 (2) 102,400 (16) 1,638,400 25,600 (32)
P1 (WC3 x WI79 [WI79-4]) P1A[8] G6 25,600 (32) 25,600 (32) 25,600 (64) 51,200 (32) 819,200
Parental rotavirus strains
Bo/WC3 P7[5] G6 102,400 (8) 409,600 (2) 51,200 (32) 204,800 (8) 204,800 (4)
Hu/WI79 P1A[8] G1 102,400 (8) 25,600 (32) 12,800 (128) 25,600 (64) 102,400 (8)
Hu/SC2 P2A[6] G2 6,400 (128) 409,600 (2) 3,200 (512) 1,600 (1,024) 3,200 (256)
Hu/WI78 P1A[8] G3 6,400 (128) 6,400 (128) 819,200 (2) 6,400 (256) 3,200 (256)
Hu/BrB P2A[6] G4 3,200 (256) 1,600 (512) 800 (2,048) 1,63,8400 (1) 12,800 (64)
Abbreviations: Hu, human; Bo, bovine.
a Neutralization titer is deﬁned as the highest serum dilution which inhibits N60% of infectious foci measured by ﬂuorescence. Homologous titers are underlined and in boldtype.
Heterologous titers of b20-fold are indicated in bold, while heterologous titers of N20-fold are shown in normal fonts (Ciarlet and Estes, 2002). Numbers in parentheses next to the
heterologous neutralization titers specify the fold differences between each heterologous strain and the homologous strain.
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serum to the P1 reassortant showed a moderate (8-fold) heterotypic
response to the G3 reassortant (Table 4).
The responses to the parental strains WI79, SC2, WI78 and BrB
were largely homotypic (Table 4). In each case, only a homotypic anti-
serum (sharing either a VP7 or a VP4 type) was able to neutralize the
HRV parental strains. WI79 was neutralized by sera raised to each the
G1 and P1 reassortants since it was the source for both the VP7 and
the VP4 of the G1 and P1 reassortants, respectively. SC2 and BrB were
neutralized by the serum raised against the G2 reassortant and the G4
reassortant, respectively. The BRV parent, WC3, was neutralized by all
the sera except for the serum raised to the G3 reassortant. The WI78
parent was strongly neutralized by the G3 antiserum (suggesting a
strong VP7 response) but was not neutralized by the P1 antiserum
even though they share the same P serotype.
Infectivity of the reassortant rotavirus strains in RotaTeq® in
neuraminidase-treated MA104 cells
The P5B[3] simian RRV strain (contained in RotaShield®) depended
on the presence of SA residues on the cell surface for efﬁcient bindingFig. 6. Effect of neuraminidase (Arthrobacter ureafaciens) treatment of MA104 cells on the in
RotaTeq®. Viral infectivity was expressed as the percentage of FFU in neuraminidase-treated
the arithmetic means of at least four replicate experiments. Error bars represent 1 standardand infectivity (Fig. 6), as shown previously (Ciarlet and Estes, 1999;
Ciarlet et al., 2002b). The binding and infectivity of the ﬁve reassortant
rotavirus strains contained in RotaTeq®, G1, G2, G3, G4, and P1, were
unaffected by neuraminidase treatment of MA104 cells, and were
therefore, SA-independent (Fig. 6). In agreement with the results of
previous studies (Ciarlet et al., 2001, 2002b), the P7[5]G6 parental BRV
strainWC3, which is the background rotavirus strain for all reassortant
strains of RotaTeq®, was SA-independent (Fig. 6). As expected, the
parental HRV strainsWI79 (P1A[8]), SC-2 (P2A[6]), WI78 (P1A[8]), and
BrB (P2A[6]) did not require the presence of SA residues on the cell
surface for efﬁcient infectivity (data not shown) as all other P1A[8] and
P2A[6] HRV strains analyzed to date (Ciarlet and Estes, 1999; Ciarlet
et al., 2002b).
Discussion
The BRV WC3 strain was selected to develop a multivalent vaccine
using a modiﬁed Jennerian approach by taking advantage of the natural
propertyof rotaviruses to reassort in cell culture. The resultingmultivalent
vaccine, RotaTeq®, is composed of human-bovine reassortants containing
thegeneticbackgroundof theBRVWC3withhumanrotavirus surfaceVP4fectivity of the reassortant rotavirus strains, G1, G2, G3, G4 (P7[5]) and P1 (P1A[8]) of
cells with respect to those obtained in control (DMEM-treated) cells. Values shown are
error of the mean. The P5B[3] SA-dependent simian RRV strain is included as control.
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worldwide [reviewed in (Ciarlet and Schödel, 2009)]. This study describes
thecompletemolecular andantigenic characterizationof the5 reassortant
rotavirus vaccine strains contained in the oral pentavalent rotavirus
vaccine, RotaTeq®, and their sensitivity to neuraminidase treatment of
cells for efﬁcient biding and infectivity. To our knowledge, this is the only
comprehensive report of the molecular characterization of a licensed,
previously licensed, or candidate rotavirus vaccine.
Due to resolution limitations of SDS-PAGE methods, it is often
difﬁcult to distinguish small differences in migration among different
rotavirus gene segments (Jones et al., 2003); therefore, the parental
origin of each gene segment was conﬁrmed by sequencing. Unexpect-
edly, the sequencing analyses revealed that two of the reassortant
viruses,G1andG2, contained aVP3genederived fromahumanparental
strain (WI79) instead of the intended VP3 gene from BRV strain WC3.
However, the G1 and G2 reassortant strains were not derived again
because (i) the safety, immunogenicity, and efﬁcacy of these two
reassortants have been established in Phase II studies of RotaTeq®
(Clark et al., 2003), (ii) the human VP3 gene within the BRV backbone
does not appear to confer a replication disadvantage (data not shown),
and (iii) the HRV strainWI79 was passaged 24 times in cell culture and
adapted to tissue culture before the G1 and G2 reassortants were
generated and subjected to further passages (13 and 11, respectively) in
cell culture.
All the 12 proteins in the 5 reassortants present in RotaTeq® have a
high level of identity with those of well-characterized HRV and BRV
references strains, and included all major conserved motifs. The BRV
WC3 backbone virus was itself studied as a vaccine candidate and was
shown to be safe and immunogenic even in high doses, but was not
consistently efﬁcacious in protecting infants from rotavirus disease
(Clark et al., 1988). The presence of human proteins in the reassortants
did not alter the safety proﬁle of the vaccine and provided consistently
high efﬁcacy against severe rotavirus gastroenteritis (RVGE) and RVGE
of any severity across the Phase II and III studies of RotaTeq® (Ciarlet
and Schödel, 2009; Heaton and Ciarlet, 2007; Heaton et al., 2005).
Phylogenetically all the genes of the strains of RotaTeq® with a BRV
origin clustered closely with previously gene sequences of BRV WC3,
other BRV rotaviruses, or rotavirus strains isolated from othermembers
of the Bovidae or Camelidae family (llama, guanaco, antelope, buffalo,
sheep), which are believed to possess genome constellations closely
related to those of BRVs (Bányai et al., 2009b; Matthijnssens et al.,
2009b). The genes of the strains of RotaTeq®withaHRVorigin clustered
closely with human rotaviruses isolated in the 1970s, 1980s and 1990s,
as expected since the HRV parental strains were isolated between 1981
and 1984.
However, most of the currently circulating HRV strains do not cluster
in the lineages containing the vaccine strains. The majority of the
currently circulatingG1 strains canbe found in theG1 lineage1 (Khamrin
et al., 2007; Parra et al., 2005; Paul et al., 2008; Trinh et al., 2007a),
whereas the G1 component of RotaTeq® is in the G1 lineage 3
(Supplementary Data 10). For G2, the majority of the HRV strains
currently circulating can be found in the G2 lineages 4 and 5 (Arista et al.,
2005; Khamrin et al., 2007; Paul et al., 2008), whereas the G2 component
of RotaTeq® is in the G2 lineage 2 (Supplementary Data 11). The
monophyletic human subcluster of the G3b phylogenetic tree can be
further subdivided in a bottomand top subclusters (Fig. 5 Supplementary
Data 12). The bottom subcluster containing the G3 component of
RotaTeq®, contains G3P1A[8] strains isolated in the USA between 1975
and 1991 (McDonald et al., 2009), whereas most of the currently
circulating G3 strains are located inside the top subcluster (Fig. 5
Supplementary Data 12) (Trinh et al., 2007b; Wang et al., 2007; Wang
et al., 2009). The G4 component of RotaTeq® is not very closely related to
any known G4 HRV, but can be found in a large human subcluster inside
theG4phylogeneticdendrogram(Fig. 5), containingmostof the currently
circulating humanG4 rotaviruses (Bucardo et al., 2007; Parra et al., 2005).
Although the VP7 proteins of the G1-G4 HRV strains currently circulatingare not very closely related to those of the G1-G4 strains in RotaTeq®,
phase III studies in theUS, EU and Latin America showed that RotaTeq® is
efﬁcacious against severe RVGE caused by the currently circulatingG1-G4
and G9 strains (Vesikari et al., 2006). In addition, the genetic analysis of
the RotaTeq® reassortants reveals that an evenwider range of protection
may be achieved due to the inclusion of P1A[8] and G6 serotypes in the
vaccine. It should, however, be emphasized that continuedmonitoring of
rotavirus genotypes, and lineages inside these genotypes, will be crucial
as vaccine-induced selective pressure might select HRV strains which
may be resistant to the protective mechanisms induced by the vaccine
(Matthijnssens et al., 2009a).
Due to a lack of proofreading ability of the rotavirus RNA-dependent
RNA polymerase, the rotavirus mutation rate suggests that, for each
round of replication, at least onemutationwould be introduced into the
rotavirus genome. The reassortants of RotaTeq® undergo two rounds of
replication cycles in cell culture during the expansion from the MSL
material to the ﬁnal PVL material, which is used to ﬁll the ﬁnal dosing
tubes. Despite the high rotavirus mutation rate, RotaTeq® exhibits a
high degree of genetic stability. In the more than 90,000 base pairs
whichwere comparedbetween theMSL and PVLmaterial, nomutations
were detected. At four nucleotide positions, genetic polymorphisms
were identiﬁed but none of these represented anymutations because in
each case, any variantpresent in the PVLmaterialwasalso present in the
MSL material, reﬂecting the presence of a quasispecies typical of RNA
viruses (Ciarlet et al., 1997; Domingo et al., 1985). In addition, it was not
surprising that the polymorphism sites were present on the VP4 and
VP7 proteins as these are subject to evolutionary pressure by the host
immune system(Bányai et al., 2009a).However,we cannot rule out that
polymorphism existed in the original plaque isolated virus and
mutations did not occur in the passage of the plaque puriﬁed virus
which gave rise to the MSL material. More extensive sequencing
analyses, such as ultra deep parallel sequencing, are necessary to
conﬁrm if no mutations are present in the RNA populations evaluated.
Nucleotide and aa acid substitutions among the same BRV genes of
someof the reassortantswere noted. However, thesewere notmutations
as each reassortant viruswas derived separately fromdifferent BRVWC3
material, and during derivation, each reassortant underwent several
passages in cell culture, followed by one or more plaque puriﬁcation
steps. Therefore, these differences reﬂect the selection of different WC3
genomic variants present in the original heterogenous WC3 virus
population (quasispecies) co-existing in a dynamic equilibrium (Dom-
ingo et al., 1985). There is no current x-ray crystal structure of anyprotein
of the reassortant strains. Future protein structure analyses may reveal
the biological relevance of the amino acid changes observed among the
reassortant strains.
The reassortant viruses in RotaTeq® were all capable of inducing
serotype-speciﬁc and cross-neutralizing antibodies in rabbits. However,
the heterotypic responses were not consistent among all the reassor-
tants; several reports have shown that the particular VP4–VP7
combination can affect antigenicity of the virus (Chen et al., 1992;
Lazdins et al., 1995). The polyclonal antibodies generated against theG1,
G2, G3, and G4 reassortant rotavirus strains showed various degrees of
cross-reactivity among the G1, G2, G3, and G4 reassortant rotavirus
because all these reassortants share the same VP4 serotype-speciﬁcity,
and neutralizing antibodies were generated to both VP4 and VP7. The
different degrees of cross-reactivity are possibly due to the different VP7
antigens in each of the viruses. However, the four antisera were able to
discriminate (N20-fold reactions) against the P1 reassortant rotavirus
strain, as it possesses different VP4 and VP7 serotype-speciﬁcities from
those of the G1, G2, G3, and G4 reassortant rotavirus strains. The
antiserum generated against the P1 reassortant rotavirus strain did not
neutralize the G1, G2, or G4 reassortant rotavirus strains. However, the
P1 reassortant rotavirus strain did showone-wayneutralization reaction
against the G3 reassortant rotavirus strain. Therefore, our data allowed
distinguishing the P1 reassortant rotavirus strain from the rest of the
reassortants, but the G1, G2, G3, and G4 reassortant rotavirus strains
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strains share the same VP4 serotype. These results indicate that the ﬁve
reassortant rotavirus strains are immunogenic, and also highlight the
immunogenic capability of VP4, which has a role in protective immunity
(Ciarlet and Estes, 2002).
The high cross-neutralizing (or heterologous) reactivity of the
antiserum raised to the G2 reassortant strain (G2P7[5]) was probably
due to VP4 because the same antiserum was able to equally and
effectively neutralize both the parental bovine WC3 strain (G6P7[5])
and thehuman strain SC2 (G2P2A[6]). ThehumanSC2strain only shares
the VP7 type (G2)with the G2 reassortant strain, while the bovineWC3
strain only shares the VP4 type (P7[5]) with the G2 reassortants strain.
Among all the reassortant strains, the G2 reassortant strain is the one
that grows the best in cell culture and it is the most stable (data not
shown). The higher stability of the G2 reassortant when compared to
the other reassortant strains may help explain why the cross-reactivity
of the antiserum raised to the G2 reassortant strain was greater to the
reassortant strains G1, G3 and G4 than the cross-reactivity of the
antisera raised to theG1, G3 andG4 reassortant strain to the reassortant
strains containing the same VP4 serotype (P7[5]). It is not possible to
predict if the particular combinations of each of the reassortants strains
of RotaTeq® will interfere with immunogenicity against the included
serotypes, but clinical data has shown protection against at least all
human G or P serotypes included in the vaccine (Ciarlet and Schödel,
2009; Heaton and Ciarlet, 2007; Vesikari et al., 2006).
Rotavirus vaccine development has taken on new signiﬁcance
following the possible association of a previously licensed rotavirus
vaccine, RotaShield®,with intussusception. It has been hypothesized that
the cell tropisms of the viruses contained in RotaShield®mayhave been a
factor in the adverse responseof intussusception in somechildren (Ciarlet
and Estes, 2001). Unlike the BRVWC3-based reassortant rotavirus strains
contained in RotaTeq®, the simian RRV strain and the reassortant
rotavirus strains of RotaShield® are SA-dependent, a function that
correlates with the VP4 genotype ( Ciarlet et al., 2002b). Consistent with
the majority of HRV strains, the G1, G2, G3, G4, and P1 reassortant
rotavirus strains of RotaTeq® are SA-independent because the infectivity
of the reassortants did not depend on SA residues on the cell surface. Our
results also conﬁrmed that the SA residue binding ability of the
reassortant rotavirus strains contained in RotaTeq® was not altered by
the different VP4–VP7 interactions. Therefore, like the parental BRV strain
WC3 (P[5]), other P[5] BRV strains (UK, B-641, 678), and a P[5] porcine
rotavirus strain (4 S) (Ciarlet and Estes, 1999; Ciarlet et al., 2002b), the
infectivity of theG1, G2, G3, andG4 reassortant rotavirus strainswere still
found to be SA-independent regardless of the association of the P[5] VP4
genotype with different VP7 types. Likewise, the infectivity of the P1
reassortant, in which the P1A[8] type is associated with a G6 VP7,
remainedunaffectedby the treatment of cellswithneuraminidase, like all
P1A[8] HRV strains analyzed to date (Ciarlet and Estes, 1999; Ciarlet et al.,
2002b).
The interactions between SA-dependent and SA-independent
rotaviruses and intestinal cells are distinct, and may explain
differences in the pathogenesis and outcome of infections (Ciarlet
and Estes, 2001; Ciarlet et al., 2001, 2002b). The uptake of SA-
dependent and SA-independent rotavirus is different at the apical and
basolateral surfaces of polarized intestinal cells grown on permeable
ﬁlters containing 0.4 µm pores (Ciarlet and Estes, 2001; Ciarlet et al.,
2001). SA-independent rotaviruses, including the BRVWC3 strain that
serves as the background for RotaTeq®, enter polarized cells by either
the apical or basolateral surface of the cells, while SA-dependent
rotaviruses, including the RRV strain that served as the background for
RotaShield®, only infects efﬁciently by the apical surface of the cells
(Ciarlet and Estes, 2001; Ciarlet et al., 2001). The pathogenesis of
RotaShield®-associated intussusception is unknown. However, it is of
interest to note that HRV strains, which have not been consistently
associated with intussusception, and the RRV strain, which has been
associated with intussusception, differ with respect to their depen-dence on SA for cell entry. Therefore, it may be prudent to select
vaccine strains that closely mimic the pathway of entry of HRV strains
into polarized cells because the interactions between rotaviruses and
intestinal cells may affect viral pathogenesis and resulting adverse
events.
This study was performed to characterize the molecular and
biological properties that deﬁne the pentavalent rotavirus vaccine,
RotaTeq®. We have shown that the vaccine is genetically stable,
contains no uncommon sequence motifs, and is representative of each
corresponding genotype. In addition, the individual PVLmaterial of each
reassortant vaccine strain is uniform, suggesting that themanufacturing
process is consistent for each reassortant rotavirus strain. Upon
formulation, each reassortant strain PVL material is diluted, and after
mixing, constitutes about 15% of the total volume of the vaccine. The
results of this study support the large body of consistent clinical data
deﬁning RotaTeq® to be immunogenic, efﬁcacious, and well tolerated
Ciarlet and Schödel, 2009). In all, the availability of the complete
genome sequencing of the 5 reassortant strains contained in RotaTeq®
will offer public health beneﬁts because it will allow development of
appropriate genotyping assays for all of the unique genome segments of
the 5 reassortant strains, and thus, permit a comprehensive epidemi-
ological surveillance or monitoring of the effectiveness and safety
program of RotaTeq®, including assessment of the potential of the
vaccine strains to transmit to unvaccinated contacts and potential to
generate reassortant rotavirus strains with wild type rotavirus strains.
Materials and methods
Parental and reference viruses
Parental HRV strains WI79 (G1P1A[8]) and WI78 (G3P1A[8]) were
isolated in 1983 fromstool samples of patients at the Children's Hospital
of Philadelphia (CHOP), and the other parental HRV strains, SC-2
(G2P2A[6]) and Bricout B (BrB) (G4P2A[6]), were isolated in 1981 and
1984, respectively, from stool samples of patients at St. Christopher's
Hospital of Philadelphia and L' Hôpital Armand Trousseau (Paris,
France), respectively. Following 24 (WI79, WI78 and BrB) to 29 (SC2)
passages in African greenmonkey kidney (MA104) cells (BioWhittaker,
Walkersville, MD), all parental HRV strains were adapted to cell culture
prior generation of reassortant strains. The parental BRV strain WC3
(G6P7[5]) was isolated in 1981 from a calf with diarrhea in Chester
County, PA, and adapted to cell culture upon 12 cell passages, with the
initial passage being performed in primary African green monkey
kidney (AGMK) cells and followed by the remainder of the cell culture
passages in MA104 and CV-1 (also African green monkey kidney) cells
(Clark et al., 1986). Upon adaptation to cell culture, no WC3 calf stool
material remained. The simian rhesus rotavirus 2 strain [RRV-2 (MMU
18006)] (G3P5B[3]) was originally isolated from the feces of a 3 and a
half-month-old rhesus monkey with diarrhea at the California Primate
Research Center, University of California (Davis, CA). RRV and the
parental BRV and HRV strains were obtained from H. F. Clark (Wistar
Institute, Philadelphia, PA). The parental BRV and HRV strains and the
RRV strain were propagated in MA104 cells in the laboratory, in the
presence of trypsin as described (Ciarlet et al., 2002b).
Generation of reassortant rotavirus strains
Theorigin and generation of thehuman-bovine reassortantsWI79-9,
SC2-9,WI78-8, BrB-9, andWI79-4 (designated as G1, G2, G3, G4, and P1
reassortant, respectively for simplicity) of RotaTeq® have been
described previously (Clark et al., 1996; Heaton et al., 2005; Ofﬁt et al.,
2003). The generation and passage history of the reassortant strainswas
carried out in Dr. H. Fred Clark's laboratory at CHOP. In general, the
passage history of each of the reassortant strains is complex. The
generation and passage history of each reassortant strain included one
co-infection (between selected parental strains), isolation of plaques,
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AGMK, MA104, CV-1 and/or Vero cells. In some instances, mixed virus
populations were treated with speciﬁc antisera to selectively remove
viruses of one parental type or expressing one speciﬁc surface protein
(VP4 andVP7), prior to subsequent cell culture passages. Noneutralizing
antibodies were employed in any of the steps to generate the G2, G3 or
P1 reassortant strains. For the G1 reassortant strain, a guinea pig
hyperimmune serum to WC3 was employed for the initial co-infection
between WC3 and WI79. A rabbit hyperimmune serum to WC3 and a
rabbit hyperimmune serum raised to theWI79-4 (P1) reassortant strain
were employed at different stages of generation of the G4 reassortant
strain. Counting theﬁrst initial co-infection, the total number of passages
in cell culture to obtain each of the reassortant strainswas 13, 11, 55, 65,
and 30 for G1, G2, G3, G4, and P1 reassortant strains, respectively. The
numbers of passages from the last plaque puriﬁcation step to the last
viral stock generated in Vero cells ranged from 2 to 9, depending on the
reassortant strain.
Master seed lot (MSL) and production validation lot (PVL) material
At Merck & Co., Inc., the reassortant rotavirus strains were prepared
by infecting Vero (African greenmonkey kidney) cells (ATCC, Manassas
VA) in the presence of trypsin using a proprietary low protein kidney
medium to generate the individual Master Seed Lot (MSL) material.
Three days post-infection, the viruses were harvested and processed by
3 freeze/thaw cycles, ﬁltration and concentration, and subsequently
stored at−70 °C prior to analysis.
A process validation lot (PVL) was manufactured by expanding
frozenMSLmaterial in Vero cells into a Stock Seed lot. The Stock Seed lot
was subsequently expanded again in Vero cells, and used in the
production of the PVL. Therefore, two infection cycles separateMSL and
PVL samples. PVL are used to formulate the ﬁnal dosing tube of the
vaccine. Both MSL and PVL materials contained a mixture of cell lysate
and viral particles. MSL and PVLmaterials were prepared separately for
each reassortant strain.
Extraction of genomic RNA
Genomic RNA from each reassortant virus from both Master Seed
and a process validation lot was extracted from frozen viral stocks
using phenol-chloroform in the presence of Trizol (Invitrogen,
Carlsbad CA) according to the manufacturer's instructions, precipi-
tated with isopropanol for 10 min, and suspended in deionized water
prior to storage at −70 °C.
Elecropherotyping of viral genomes
The RNA electropherotypes of the reassortant and parental
rotavirus strains were analyzed by PAGE and silver staining. Cell
lysate samplesweremixedwith reducing buffer (2% SDS, 20% glycerol,
5 M urea, 4% 2-mercaptoethanol, 0.1% bromophenol blue) and heated
at 68 °C for 10 min. All samples were subjected to electrophoresis at
150 volts for 3 hours in 8% TRIS-glycine polyacrylamide gelsTable 5
Accession numbers of all the genome segments of each of the reassortant rotavirus vaccine
Reassortant
Rotavirus
GenBank Accession numbers*
VP7 VP4 VP6 VP1 VP2
WI79-9 (G1) GU565057 GU565055 GU565056 GU565052 GU565053
SC2-9 (G2) GU565068 GU565066 GU565067 GU565063 GU565064
WI78-8 (G3) GU565079 GU565077 GU565078 GU565074 GU565075
BrB-9 (G4) GU565090 GU565088 GU565089 GU565085 GU565086
WI79-4 (P1) GU565046 GU565044 GU565045 GU565041 GU565042(Invitrogen) using TRIS-glycine SDS running buffer (Invitrogen). The
resulting migration patterns of the genome segments were visualized
by staining the gel with silver nitrate (BioRad, Hercules CA).Sequencing of viral genomes
One-step reverse transcription and PCR of RNA from MSL and PVL of
each reassortant was performed using gene speciﬁc primers from each
genomic segment. Superscript (Invitrogen) master mix was prepared
according to themanufacturer's instructions andadded toa96-well plate;
primerswere then added followed by template. The platewas sealed and
centrifuged prior to thermocycling according to the manufacturer's
recommended conditions. The resulting DNA fragments were puriﬁed
using a 96-well puriﬁcation column (Millipore, Billerica MD). The
integrity of the fragments was monitored by agarose gel electrophoresis.
Primer sequences used to amplify the 11 genome segments can be found
in Supplementary Data 1.
The full lengths of the segments were sequenced by primer walking
on an ABI 3730xl instrument using ABI BigDye 3.1 chemistry. Each base
was sequenced a minimum of four times (twice in each direction) to
ensure high ﬁdelity and the consensus sequences were assembled by
theSequencher®softwarepackage (GeneCodes Corp., AnArbor,MI). To
determine the 5' and 3' end of each gene segment the SMART™ RACE
cDNA ampliﬁcation kit from Clontech was used according to the
manufacturer's instructions. Internals gene speciﬁc primers were
designed based on the known internal sequences of each gene segment
and can be obtained upon request. Partial sequences of the gene
segments from parental strains were obtained at lower ﬁdelity (one
read-through per base on average). MSL sequences were submitted to
GenBank and accession numbers of each of the rotavirus gene segments
of the 5 reassortant strains contained in RotaTeq® are shown in Table 5.Assignment of parental origin of gene segments
MSL sequences and partial gene segments from parental viruses
were aligned using Vector NTI (Invitrogen). The gene sequence from
the rotavirus parent (bovine or human) with the highest identity to
the vaccine reassortant gene segment was assigned as the parent.Alignments and phylogenetic analysis
Phylogenetic and molecular evolutionary analyses were conducted
using the MEGA version 4.1 software (Kumar et al., 2001). Genetic
distances were calculated using the Kimura-2 correction parameter at
the nucleotide level, and the phylogenetic trees were constructed using
the neighbor-joining method with 500 bootstrap replicates. The entire
open reading frame (ORF) of each of the gene sequences of the 5
reassortant rotavirus strains determined in the studywere compared to
other rotaviruses sequences from a broad range of human, bovine, and
animal genotypes available in GenBank. Genotypes were determined
using the online RotaC classiﬁcation tool, according to the guidelines of
the RCWG (Maes et al., 2009; Matthijnssens et al., 2008b).strains of RotaTeq® in Master Seed Lot (MSL) material.
VP3 NSP1 NSP2 NSP3 NSP4 NSP5
GU565054 GU565058 GU565059 GU565060 GU565061 GU565062
GU565065 GU565069 GU565070 GU565071 GU565072 GU565073
GU565076 GU565080 GU565081 GU565082 GU565083 GU565084
GU565087 GU565091 GU565092 GU565093 GU565094 GU565095
GU565043 GU565047 GU565048 GU565049 GU565050 GU565051
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While sequencing the reassortant VP4 and VP7 gene segments of the
G2, G4 and P1 reassortant strains, four of the bases were not resolved. It
was not clear if these bases were due to polymorphisms or a sequencing
anomaly. Therefore, the presence of polymorphisms was investigated
using the reference method for analysis of quasispecies distribution
within a population (Malet et al., 2003). RT-PCR (Thermoscript,
Invitrogen) was performed onMSL and PVL of G2, G4 and P1 reassortant
strain, using primers ﬂanking the site of putative dimorphic bases. The
sequences of the primer pairs used for PCR ampliﬁcationwere: 1) For P1,
VP7: RTAFor1/24 (5'-TCCGTTTGGCTAGCGGTTAGCTCC-3') and
RTRev1007/1031 (5'-CAACTCTAATCTAACATGCACCTAC-3'). 2) For P1,
VP4: P1/v4/For (5'-TTATTCCAAGGTCTCAAGAGTCTAA-3') and P1/v4/
Rev (5'-CCAGCAAAATGTAACGAAACA-3'). 3) For G2, VP4: G2/v4/For (5'-
CAATTCTGGCAGATGGTTATCT-3') and G2/v4/Rev (5'-GCCCAAACCTCCA-
GATTTTATTA-3'). 4) For G4, VP4: G4/v4/For (5'-TGAG GTAAGGCCATA-
TAGTGACTT-3') and G4/v4/Rev (5'-TCGACTGCCAGTCTAAATCTAA AC-
3'). The resulting PCR productswere cloned into the Zero Blunt TOPOPCR
vector (Invitrogen), and the identity of the dimorphic nucleotide was
determined by sequencing ofmultiple clones (10–16) using the universal
M13-Forward or M13-Reverse primers.
Production of reassortant-speciﬁc hyperimmune sera
Triple-layered particles (TLPs) from each reassortant virus and their
respective parental strains were puriﬁed from infected cell lysates by
centrifugation through a 35% sucrose cushion diluted in tris-sodium-
calciumbuffer (10 mM tris (pH 7.5), 140 mMNaCl, and 10mMCaCl2) to
maintain the outer capsid proteins, followed by CsCl isopycnic
centrifugation (Ciarlet et al., 1998).
The puriﬁed TLPs (200 µg) were injected intramuscularly into
rotavirus-negative New Zealand rabbits with Freund's complete
adjuvant. Boost inoculations of 100 µg of TLPswith Freund's incomplete
adjuvant were administered on days 28, 56, and 84. On day 97 the
rabbits were euthanized and the (hyperimmune) serum was collected
from the individual animals.
Fluorescent focus neutralization assay (FFNA)
The hyperimmune sera raised against each of the ﬁve reassortant
rotaviruseswere testedbyaﬂuorescent focusneutralizationassay (FFNA)
todetermine thehomotypic andheterotypic responsesof theneutralizing
antibodies raised to each of the reassortant rotavirus strains as described
previously (Ciarlet et al., 1994). Generally, when hyperimmune sera are
prepared, the majority of the neutralizing antibodies are generally raised
to VP7, but neutralizing antibodies to VP4 can also be generated (Ciarlet
et al., 1997; Matsuda et al., 1993; Snodgrass et al., 1992). The potential to
generate antibodies to both outer capsid proteins (VP4 and VP7) may
depend on the particular VP4/VP7 combination (Chen et al., 1992;
Ciarlet et al., 1997; Lazdins et al., 1995).
Viral infectivity assays
The N-acetylneuraminic (sialic) acid (SA) dependence or indepen-
dence of infectivity of the parental rotavirus strains and the G1, G2, G3,
G4, and P1 reassortant rotavirus strains was measured in conﬂuent
MA104 cells grown in 96-well plates as described (Ciarlet and Estes,
1999; Ciarlet et al., 2002b), with minor modiﬁcations. The SA-
dependent simian RRV strain (G3P5B[3]) was used as a control in all
assays. Brieﬂy, MA104 cells were treated for 1 hr at 37 °C with 100 μl of
two-fold dilutions of neuraminidase from Arthrobacter ureafaciens
puriﬁed by afﬁnity chromatography (Sigma Chemical Co., St. Louis,
MO), starting from 40 mU/mL or with 100 µl of Dulbecco's modiﬁed
Eagle's medium (DMEM; Invitrogen Corporation, Long Island, NY) as a
control. Following treatment with neuraminidase, cells were washedwith DMEM prior to inoculation with a single dilution (depending on
rotavirus strain) of 100–300 focus forming units (FFU) per well. After
allowing virus adsorption for 2 hr at 37 °C, the inoculum was removed
and cells were washed with DMEM. Cells were incubated for 16 to 18 h
at 37 °C with DMEM, washed with PBS, ﬁxed with cold methanol,
probed with a 1:800 dilution in PBS of an anti-rotavirus hyperimmune
guinea pig serum (kindly supplied by Richard Ward, Cincinnati
Children's Hospital Medical Center, Cincinnati, OH), and stained for
ﬂuorescent focus assay (FFA) with a 1:200 dilution in PBS of goat anti-
guinea pig-speciﬁc immunoglobulins conjugated with ﬂuorescein
isothiocyanate (FITC, INC Biomedicals Inc., Aurora, OH). Infectivity
assays were performed at least four times with each virus strain. Viral
infectivity was expressed as the percentage of FFU in neuraminidase-
treated cells with respect to those obtained in control (DMEM-treated)
cells. If infected cells were ﬁxed and stained immediately after the
adsorption period, no ﬂuorescent foci were observed (data not shown).Acknowledgments
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